每经AI快讯，泰林生物10月17日晚间发布公告称，浙江泰林生物技术股份有限公司全资子公司浙江泰 林生命科学有限公司、浙江泰林分析仪器有限公司于近期共取得了2项专利证书。专利名称分别为"微生 物检测分析仪""一种一体式两虫玻片压平装置"等。 （记者 曾健辉） 每经头条（nbdtoutiao）——"我还在！"林园硬气回应牛市亏钱，"接下来，我还会在！"坚持白酒是"快 乐需求"，科技股买了"愁得睡不着" ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-078 2025 年 10 月 17 日 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林分析仪器有限公司（以 下简称"泰林分析仪器"）于近期共取得了 2 项专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 微生物检测分析仪 | 外观 | 2025300291612 | 2025/10/10 | 泰林分析仪器 | | 2 | 一种一体式两虫玻片压平装置 | 实用新型 | 2024226093270 | 2025/10/17 | 泰林生命科学 | 上述专利的取得不会对公司及全资子公司泰林生命科学、泰林分析仪器近期 生产经营产生重大影响，但有利于公司及全资子公司泰林生命科学、泰林分析仪 器进一步完善知识产权保护体系，发挥自主知识产权优势，并形成持续创新机制， 保持技术领先地位，提升核心竞争力。 特此公告。 浙江泰林生物技术股份有限公 ...

每经AI快讯，10月16日，泰林生物（300813）公告，青岛高得投资合伙企业(有限合伙)作为控股股东、 实际控制人的一致行动人，计划自2025年7月16日起15个交易日后的3个月内，通过集中竞价、大宗交易 等方式减持不超过181.95万股，占公司总股本的1.50%。截至2025年10月15日，高得投资实际减持 181.18万股，占公司总股本的1.49%，减持计划已完成。减持后，高得投资持有546.63万股，占公司总 股本的4.51%。 ...

泰林生物公告，高得投资于2025-8-8至2025-10-15通过集中竞价和大宗交易分别减持121.18万股和60万 股，减持价格区间24.35-42.01元/股，大宗交易价格27.69元/股，合计减持181.18万股，占公司总股本 1.4949%；减持后持股546.63万股，占4.51%。 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-077 浙江泰林生物技术股份有限公司 关于持股 5%以上股东暨控股股东、实际控制人的一致行动人 减持股份结果公告 一、股东减持情况 公司控股股东、实际控制人叶大林先生、倪卫菊女士及其一致行动人青岛高 得投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 | 股东 | 减持方式 | 减持期间 | 减持价格区 | 减持均价 | 减持股数 | 减持比例 | 股份来源 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | 间（元/股） | （元/股） | （万股） | （%） | | | 高得 | 集中竞价 交易 | 2025-8-8 至 2025-9-24 | 24.35-42.01 | 34.13 | 121.177 | 0.9998 | 首次公开发行前 已发行的股份及 | | 投资 | 大宗交易 | 2025-10-15 | 27.69 | 27.69 | 60 | 0.4951 | 因历次资本公积 | | | | | 合 ...

Core Points - TaiLin Bio's stock closed at 32.87 CNY, with a rise of 0.89% on October 15 [1] - The company experienced 8 block trades totaling 600,000 shares and a transaction value of 16.61 million CNY [1][2] - The average transaction price for the block trades was 27.69 CNY, with a consistent discount of 15.76% [1][2] Transaction Details - The first four transactions involved 72,300 shares each, with a total value of 2.00 million CNY per transaction [1] - The fifth transaction involved 86,200 shares, totaling 2.39 million CNY [2] - The seventh transaction involved 80,000 shares, totaling 2.22 million CNY [2] - The total transaction value for the last three months amounted to 16.61 million CNY, with a net outflow of 15.67 million CNY in the last five trading days [2]

Core Viewpoint - Tailin Bio announced the acquisition of 4 patent certificates by its wholly-owned subsidiaries, Zhejiang Tailin Medical Engineering Co., Ltd. and Zhejiang Tailin Analytical Instruments Co., Ltd., including 1 invention patent [2] Group 1 - The announcement was made on the evening of October 13 [2] - The patents are expected to enhance the company's technological capabilities and competitive position in the market [2]

Market Overview - The specialized equipment sector declined by 0.43% on October 13, with Aomeisen leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Top Gainers in Specialized Equipment Sector - Lihexing (301013) saw a significant increase of 20.01%, closing at 37.90 with a trading volume of 848,000 shares and a transaction value of 3.061 billion [1] - Lingge Technology (920284) rose by 16.90%, closing at 46.01 with a trading volume of 130,000 shares and a transaction value of 561 million [1] - ST Xinyuan (300472) increased by 11.96%, closing at 6.46 with a trading volume of 376,200 shares and a transaction value of 234 million [1] Top Losers in Specialized Equipment Sector - Yunmeima (920080) experienced a decline of 8.11%, closing at 34.10 with a trading volume of 95,200 shares and a transaction value of 323 million [2] - Haoyang Co. (300833) fell by 7.94%, closing at 39.64 with a trading volume of 33,000 shares and a transaction value of 132 million [2] - Rutong Co. (603036) decreased by 6.78%, closing at 22.15 with a trading volume of 191,700 shares and a transaction value of 423 million [2] Capital Flow Analysis - The specialized equipment sector saw a net outflow of 1.135 billion from institutional investors and 170 million from retail investors, while retail investors had a net inflow of 1.305 billion [2] - Notable capital inflows included Beikang Technology (600980) with a net inflow of 99.84 million from institutional investors [3] - Zhengfan Technology (688596) had a net inflow of 64.25 million from institutional investors, while experiencing a net outflow of 113 million from retail investors [3]

Group 1 - The core point of the article is that Tailin Bio has recently obtained four patent certificates through its wholly-owned subsidiaries, indicating a focus on innovation and development in the biotechnology sector [1] - The patents include methods and devices for maintaining temperature, hydrogen peroxide gas concentration, and saturation, as well as a dual-sterilization internal circulation sterile isolator, showcasing the company's technological advancements [1] - For the fiscal year 2024, Tailin Bio's revenue composition is projected to be 90.04% from the pharmaceutical industry and 9.96% from other businesses, highlighting the company's strong reliance on the pharmaceutical sector [1] Group 2 - As of the report, Tailin Bio has a market capitalization of 4 billion yuan, reflecting its position in the market [1]

浙江泰林生物技术股份有限公司 关于取得专利证书的公告 证券代码：300813 证券简称：泰林生物 公告编号：2025-076 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 医学工程有限公司（以下简称"泰林医学工程"）、浙江泰林分析仪器有限公司（以 下简称"泰林分析仪器"）于近期共取得了 4 项专利证书（其中发明专利 1 项）， 具体情况如下： 上述专利的取得不会对公司及全资子公司泰林医学工程、泰林分析仪器近期 生产经营产生重大影响，但有利于公司及全资子公司泰林医学工程、泰林分析仪 器进一步完善知识产权保护体系，发挥自主知识产权优势，并形成持续创新机制， 保持技术领先地位，提升核心竞争力。 2025 年 10 月 13 日 特此公告。 | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种维持温度、过氧化氢气体浓度 及饱和度的方法及装置 | 发明 | 20231068158 ...